Literature DB >> 32859456

Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner.

Ran Yu1, Linbo Jin1, Fangfang Li1, Manabu Fujimoto2, Qiang Wei1, Zhenhua Lin3, Xiangshan Ren3, Quanxin Jin1, Honghua Li1, Fanping Meng1, Guihua Jin4.   

Abstract

BACKGROUND: It has been shown that dihydroartemisinin (DHA) is effective in the treatment of malaria. Recently studies have demonstrated that DHA also regulates tumor cell growth, angiogenesis, T cell differentiation and generation. However, how DHA affects melanoma development remains poorly defined.
OBJECTIVES: To investigate the effects of DHA on the proliferation and migration of melanoma in vivo and in vitro, and to explore its possible mechanism.
METHODS: B16F10 cells and melanoma-bearing BALB/c mice were used to investigate the effects of DHA on melanoma.
RESULTS: DHA had inhibitory effect on melanoma proliferation in a time-and dose-dependent manner. Treatment of DHA attenuated melanoma severity and histopathological changes in BALB/c mice. DHA also inhibited melanoma invasion, migration, and community formation in a dose-dependent manner. Flow cytometry revealed a significant increase in IFN-γ+CD8+ T cells in the DHA groups. In tumor microenvironment and spleen, DHA induced expansion of CD8+CTL, while, CD4+CD25+Foxp3+ regulatory T (Treg) cells and IL-10+CD4+CD25+ T cells were normalized by DHA treatment. DHA diminished expression of IL-10 and IL-6, and increased the expression of IFN-γ in the tumor and spleen. Moreover, DHA administration significantly promoted the mitochondrial apoptosis of melanoma by regulating the STAT3 pathway.
CONCLUSION: DHA induces mitochondrial apoptosis and alters cytokines expression by inhibiting the phosphorylation of STAT3. DHA improves anti-tumor immunity in mice through controlling CD8+CTL function by counteracting IL-10-dependent Treg cells suppression, which promises to be an alternative drug for melanoma.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD8(+)CTL; Cytokines; Dihydroartemisinin; Melanoma; Treg

Mesh:

Substances:

Year:  2020        PMID: 32859456     DOI: 10.1016/j.jdermsci.2020.08.001

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  6 in total

1.  Dihydroartemisinin regulates immune cell heterogeneity by triggering a cascade reaction of CDK and MAPK phosphorylation.

Authors:  Qilong Li; Quan Yuan; Ning Jiang; Yiwei Zhang; Ziwei Su; Lei Lv; Xiaoyu Sang; Ran Chen; Ying Feng; Qijun Chen
Journal:  Signal Transduct Target Ther       Date:  2022-07-11

2.  HLA-DRB1: A new potential prognostic factor and therapeutic target of cutaneous melanoma and an indicator of tumor microenvironment remodeling.

Authors:  Huiling Deng; Yuxuan Chen; Jiecong Wang; Ran An
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752

Review 3.  Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review.

Authors:  Ka Hong Wong; Donglin Yang; Shanshan Chen; Chengwei He; Meiwan Chen
Journal:  Asian J Pharm Sci       Date:  2022-05-14       Impact factor: 9.273

4.  Dihydroartemisinin inhibits activation of the AIM2 inflammasome pathway and NF-κB/HIF-1α/VEGF pathway by inducing autophagy in A431 human cutaneous squamous cell carcinoma cells.

Authors:  Yajie Wang; Zhijia Li; Muzhou Teng; Junlin Liu
Journal:  Int J Med Sci       Date:  2021-05-13       Impact factor: 3.738

Review 5.  Dihydroartemisinin: A Potential Natural Anticancer Drug.

Authors:  Xiaoshuo Dai; Xiaoyan Zhang; Wei Chen; Yihuan Chen; Qiushuang Zhang; Saijun Mo; Jing Lu
Journal:  Int J Biol Sci       Date:  2021-01-16       Impact factor: 6.580

6.  Dihydroartemisinin Promoted Bone Marrow Mesenchymal Stem Cell Homing and Suppressed Inflammation and Oxidative Stress against Prostate Injury in Chronic Bacterial Prostatitis Mice Model.

Authors:  Shen Li; Yongzhang Li; Xiaozhe Su; Aiyun Han; Yang Cui; Shuyue Lv; Jin Zhang; Chao Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-15       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.